Floatz logo

Isatuximab

Monoclonal Gammopathy of Undetermined Significance

Assistance Publique - Hôpitaux de Parismonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Monoclonal Gammopathy of Undetermined Significance cohort.

Asset / SponsorPhaseRating
Dfn-15
National Cancer Institute (NCI)
Phase 2B
Metformin
Dana-Farber Cancer Institute
Phase 2CCC
Linvoseltamab
Regeneron Pharmaceuticals
Phase 2CCC
Siltuximab
Janssen Research & Development, LLC
Phase 1CC
Tetanus-Cmv Fusion Peptide Vaccine
City of Hope Medical Center
Phase 1CC

View all 13 →

Same molecule, other indications

Isatuximab is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
70 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
66 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →